ENTA logo

Enanta Pharmaceuticals, Inc.

ENTA
Healthcare|Biotechnology|US
$11.00
+0.92 (+9.13%)
Tangible Book / Share
$3.47
Cash / Share
$6.51
Next Earnings Report
Nov 16, 2026
EPS est. -$0.72 · Revenue est. $14.6M
Financing Filings (last 12 months)
2
Shelf registrations / offering prospectuses — latest Jul 2, 2026 (424B5). Possible dilution.

Upcoming Data Readouts (2)

Dec 2026
Est. completion
P2RSV Infection
A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus
NCT07482657n=150
Jul 2029
Est. completion
P2P3RSV
A Study to Investigate the Efficacy and Safety of Zelicapavir Compared With Placebo in Adults With RSV Who Are at High Risk for Severe Disease
NCT07908381n=860

Recent Press Releases

Enanta Pharmaceuticals to Participate in Upcoming Investor Conferences
Nov 4, 2026 · Business Wire
Enanta Pharmaceuticals Announces Planned Retirement of Longstanding Chief Executive Officer Jay R. Luly, Ph.D.
Oct 28, 2026 · Business Wire
Enanta Pharmaceuticals Announces First Patient Dosed in the RESOLVE Phase 2b/3 Study of Zelicapavir, a Potential First-in-Disease Treatment for Respiratory Syncytial Virus (RSV)
Oct 26, 2026 · Business Wire
Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026
Oct 13, 2026 · Business Wire
Enanta Pharmaceuticals to Participate in September Investor Conferences
Sep 1, 2026 · Business Wire
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2026
Aug 10, 2026 · Business Wire

SEC Filings (58)

Last two years from EDGAR. Insider Form 4s are on the Ownership tab.

FiledFormWhat it isLinks
Oct 29, 20268-KMaterial eventDocumentIndex
Oct 28, 20268-KMaterial eventDocumentIndex
Oct 27, 2026SC 13GPassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 14, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Aug 12, 202610-QQuarterly reportDocumentIndex
Aug 10, 20268-KMaterial eventDocumentIndex
Jul 2, 20268-KMaterial eventDocumentIndex
Jul 2, 2026424B5Offering prospectusDocumentIndex
Jun 23, 20268-KMaterial eventDocumentIndex
Jun 18, 20268-KMaterial eventDocumentIndex
May 13, 2026S-8Employee stock planDocumentIndex
May 13, 202610-QQuarterly reportDocumentIndex
May 11, 20268-KMaterial eventDocumentIndex
Mar 26, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Mar 26, 20268-KMaterial eventDocumentIndex
Mar 12, 20268-KMaterial eventDocumentIndex
Feb 20, 2026EFFECTDocumentIndex
Feb 13, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Feb 11, 2026S-3Shelf registrationDocumentIndex
Feb 11, 202610-QQuarterly reportDocumentIndex
Feb 9, 20268-KMaterial eventDocumentIndex
Feb 5, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Jan 26, 2026ARSAnnual report to holdersDocumentIndex
Jan 26, 2026DEFA14AProxy / shareholder voteDocumentIndex
Jan 26, 2026DEF 14AProxy / shareholder voteDocumentIndex
Jan 20, 2026SC 13G/APassive 5%+ stakeDocumentIndex
Nov 19, 202510-KAnnual reportDocumentIndex
Nov 17, 20258-KMaterial eventDocumentIndex
Nov 13, 2025SC 13G/APassive 5%+ stakeDocumentIndex
Nov 7, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 9, 2025SC 13GPassive 5%+ stakeDocumentIndex
Oct 1, 20258-KMaterial eventDocumentIndex
Oct 1, 2025424B5Offering prospectusDocumentIndex
Sep 30, 2025424B5Offering prospectusDocumentIndex
Sep 29, 20258-KMaterial eventDocumentIndex
Sep 29, 20258-KMaterial eventDocumentIndex
Aug 27, 20258-KMaterial eventDocumentIndex
Aug 20, 20258-KMaterial eventDocumentIndex
Aug 13, 202510-QQuarterly reportDocumentIndex